BRAF and malignant peripheral nerve sheath tumor: BRAF mutant MPNST may also respond to targeted therapy; one case report described a dramatic response to the RAF inhibitor vemurafenib in a patient with sporadic metastatic MPNST harboring the BRAF V600E mutation [96].